 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma...

Adaptimmune Receives Transfer of IND for Lete-cel Program

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this yearSURPASS Phase 1...

Adaptimmune Reports Third Quarter Financial Results and Business Update

Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen toolbox in developmentPhiladelphia, Pennsylvania and...

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript...

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP  Get Free Report) shares dropped 2.5% on Friday . The stock traded as low as $0.54 and last traded at $0.54. Approximately 6,405 shares changed hands...

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 2.5%

40% (18/45) of people with synovial sarcoma or MRCLS and who have received  2 prior lines of therapy had clinical responses with lete-cel, by independent review[2]; primary efficacy endpoint...

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months (CTOS 2022)Median overall survival (mOS) was ~17...

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report...

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26...

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Baillie Gifford  Co. boosted its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP  Free Report) by 0.4% during the 2nd quarter, Holdings Channel reports. The firm owned...

Baillie Gifford & Co. Acquires 64,133 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Watchers	6,994
52-Wk Low	$0.42
52-Wk High	$2.35

Market Cap	$123.04M
Volume (M)	123.00
52-Wk High	$2.35
52-Wk Low	$0.42

ADAP Adaptimmune Therapeutics

About

Feed

News

Sentiment

Earnings

Fundamentals